Corterve
10 Studies Recruiting

Clinical Trials Near Sacramento, CA

Find research studies actively recruiting participants near Sacramento. Studies are run at established research institutions including UC Davis Medical Center and Sutter Health.

Top Research Institutions in Sacramento

1

UC Davis Medical Center

2

Sutter Health

Recruiting Studies Near Sacramento

#1

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

RECRUITINGPHASE2National Cancer Institute (NCI)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib and imatinib are in a class of medications called tyrosine kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with Ph+ or Ph-like ABL-class B-ALL than dasatinib or imatinib with chemotherapy.

📍 Birmingham, Alabama📍 Phoenix, Arizona📍 Tucson, Arizona
#2

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

RECRUITINGNot SpecifiedGuardant Health, Inc.

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

📍 Birmingham, Alabama📍 Chandler, Arizona📍 La Jolla, California
#3

Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)

RECRUITINGPHASE4University of California, Davis

This pilot randomized clinical trial compares dopamine and norepinephrine as first-line vasoactive therapies in term and late preterm neonates with pulmonary hypertension associated with hypoxemic respiratory failure and systemic hypotension. Systemic hypotension is a common and clinically significant complication of persistent pulmonary hypertension of the newborn (PPHN) and frequently requires vasopressor support to maintain adequate systemic perfusion. Dopamine is commonly used in this setting; however, prior animal experimental and clinical data suggest it may increase pulmonary vascular resistance, potentially worsening right ventricular afterload and hypoxemia. Norepinephrine may preferentially increase systemic vascular resistance with less effect on the pulmonary circulation. This study evaluates short-term hemodynamic and oxygenation responses following initiation of dopamine or norepinephrine.

📍 Sacramento, California
#4

Early Internal Fixation Versus NonOperative Care With Early Rehabilitation for LC1 Fragility Fractures of the Pelvis

RECRUITINGNAUniversity of Southern California

The goal of this randomized pilot study is to assess feasibility of the trial and to collect information to inform the design of a definitive trial. Adult patients ages 60 years or older with a low-energy lateral compression type 1 (LC1) pelvis fracture with \<10 mm initial displacement of the posterior pelvic ring will be eligible to participate in the study. Patients will be randomized to one of two treatment groups, early internal fixation or nonoperative care with early rehabilitation, defined as at least five days of attempted mobilization by rehabilitation providers. Participants will be followed for 1 year.

📍 Los Angeles, California📍 Los Angeles, California📍 Los Angeles, California
#5

Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)

RECRUITINGNAShockwave Medical, Inc.

Prospective, Multi-center, Single-arm Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE Study)

📍 Rancho Mirage, California📍 San Francisco, California📍 Park Ridge, Illinois
#6

Improving Caregiver Engagement in Early Interventions

RECRUITINGNAUniversity of California, Davis

The goal of this study is to test the effectiveness of the FANS-EI program in supporting caregiver engagement in caregiver-mediated early interventions for young children with autism. This study also examines caregiver-perceived social support and self-efficacy and FANS-EI implementation outcomes (feasibility, acceptability, appropriateness).

📍 Sacramento, California
#7

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

RECRUITINGPHASE2, PHASE3Bristol-Myers Squibb

A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy

📍 Palo Alto, California📍 Sacramento, California📍 Sacramento, California
#8

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

RECRUITINGNot SpecifiedAstellas Pharma Global Development, Inc.

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.

📍 Phoenix, Arizona📍 Scottsdale, Arizona📍 Laguna Hills, California
#9

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

RECRUITINGPHASE1, PHASE2Perceive Biotherapeutics, Inc.

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

📍 Scottsdale, Arizona📍 Encino, California📍 Sacramento, California
#10

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

RECRUITINGPHASE4American Thrombosis and Hemostasis Network

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.

📍 Little Rock, Arkansas📍 Los Angeles, California📍 Sacramento, California

Clinical Trials in Sacramento: FAQ

How do I find clinical trials near Sacramento?

Corterve aggregates all actively recruiting clinical trials near Sacramento, CA from the ClinicalTrials.gov database. Simply browse the listings on this page or take our free health assessment to find trials you may qualify for.

Are clinical trials in Sacramento free?

Yes, clinical trials are free for participants. The research sponsor covers all study-related costs. Many trials near Sacramento, CA also provide compensation for your time and travel expenses.

What research institutions are located in Sacramento?

Sacramento is home to several leading research institutions, including UC Davis Medical Center, Sutter Health. These facilities run clinical trials across Oncology, Neurology, Cardiology, and other therapeutic areas.

Ready to Find a Trial Near You?

Take our free 2-minute health assessment to see research studies recruiting near Sacramento that you may be eligible for. No insurance required.

Start Free Assessment